These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33267928)

  • 1. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Gill H; Subramaniapillai M; Kratiuk K; Nasri F; Mansur RB; Rosenblat JD
    CNS Spectr; 2022 Jun; 27(3):322-330. PubMed ID: 33267928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
    d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
    J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.
    Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
    Focus (Am Psychiatr Publ); 2023 Oct; 21(4):420-429. PubMed ID: 38694999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
    Singh B; Vande Voort JL; Pazdernik VK; Frye MA; Kung S
    J Affect Disord; 2024 Apr; 351():534-540. PubMed ID: 38302067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.
    Freeman MP; Hock RS; Papakostas GI; Judge H; Cusin C; Mathew SJ; Sanacora G; Iosifescu DV; DeBattista C; Trivedi MH; Fava M
    J Clin Psychopharmacol; 2020; 40(3):287-292. PubMed ID: 32332464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.
    Jha MK; Wilkinson ST; Krishnan K; Collins KA; Sanacora G; Murrough J; Goes F; Altinay M; Aloysi A; Asghar-Ali A; Barnett B; Chang L; Costi S; Malone D; Nikayin S; Nissen SE; Ostroff R; Reti I; Wolski K; Wang D; Hu B; Mathew SJ; Anand A
    JAMA Netw Open; 2024 Jun; 7(6):e2417786. PubMed ID: 38916891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
    McMullen EP; Lee Y; Lipsitz O; Lui LMW; Vinberg M; Ho R; Rodrigues NB; Rosenblat JD; Cao B; Gill H; Teopiz KM; Cha DS; McIntyre RS
    Adv Ther; 2021 Jun; 38(6):2795-2820. PubMed ID: 33929660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersomnia as a predictor of response to intravenous ketamine/intranasal esketamine in treatment resistant depression.
    Patarroyo-Rodriguez L; Pazdernik V; Vande Voort JL; Kung S; Singh B
    J Affect Disord; 2024 Mar; 349():272-276. PubMed ID: 38199421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
    Niciu MJ; Shovestul BJ; Jaso BA; Farmer C; Luckenbaugh DA; Brutsche NE; Park LT; Ballard ED; Zarate CA
    J Affect Disord; 2018 May; 232():310-315. PubMed ID: 29501990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anhedonia in bipolar depression treated with ketamine.
    Wilkowska A; Wiglusz MS; Arciszewska-Leszczuk A; Gałuszko-Węgielnik M; Cubała WJ
    Bipolar Disord; 2024 Jun; 26(4):356-363. PubMed ID: 38311367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital.
    Gutierrez G; Kang MJY; Vazquez G
    Psychiatry Res; 2024 May; 335():115865. PubMed ID: 38518518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.
    Rodrigues NB; Chen-Li D; Di Vincenzo JD; Juneja A; Pinder BD; McIntyre RS; Rosenblat JD
    J Psychopharmacol; 2024 Apr; 38(4):375-381. PubMed ID: 38477185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report.
    Joseph B; Nunez NA; Kung S; Vande Voort JL; Pazdernik VK; Schak KM; Boehm SM; Carpenter B; Johnson EK; Malyshev G; Smits N; Adewunmi DO; Brown SK; Singh B
    Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.
    Singh B; Parikh SV; Voort JLV; Pazdernik VK; Achtyes ED; Goes FS; Yocum AK; Nykamp L; Becerra A; Smart L; Greden JF; Bobo WV; Frye MA; Burdick KE; Ryan KA
    Psychiatry Res; 2024 May; 335():115829. PubMed ID: 38479192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous ketamine for rapid treatment of major depressive disorder in the general medical hospital.
    Gee SH; Wratten C; Cairns R; Santhouse A; Taylor D
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34645623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans.
    Miller EA; Afshar HT; Mishra J; McIntyre RS; Ramanathan D
    Psychiatry Res; 2024 May; 335():115858. PubMed ID: 38547599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective association of psychological pain and hopelessness with suicidal thoughts.
    Ballard ED; Farmer CA; Gerner J; Bloomfield-Clagett B; Park LT; Zarate CA
    J Affect Disord; 2022 Jul; 308():243-248. PubMed ID: 35429526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder.
    Yamasaki K; Hasegawa T; Takeda M
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):130-137. PubMed ID: 32162496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the potential of Esketamine in the treatment of bipolar depression.
    Dell'Osso B; Martinotti G
    Eur Neuropsychopharmacol; 2023 Dec; 77():21-23. PubMed ID: 37660440
    [No Abstract]   [Full Text] [Related]  

  • 20. Case report: Medical student types journals during ketamine infusions for suicidal ideation, treatment-resistant depression, post-traumatic stress disorder, and generalized anxiety disorder.
    Willms J; McCauley B; Kerr L; Presto P; Arun A; Shah N; Irby K; Strawn M; Kopel J
    Front Psychiatry; 2022; 13():1020214. PubMed ID: 36620675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.